PMEL and uveal melanoma: Interestingly, LNS8801 further increased the expression of gp100, a melanoma antigen that has been effectively targeted by tebentafusp, a first-in-class bispecific fusion protein, recently approved by the FDA for the treatment of uveal melanoma (37).